Meeting
2021 Gastrointestinal Cancers Symposium
Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.
Authors
Samuel J Klempner
Massachusetts General Hospital, Boston, MA
Samuel J Klempner , Jaffer A. Ajani , Salah-Eddin Al-Batran , Yung-Jue Bang , Daniel V.T. Catenacci , Peter C. Enzinger , David H. Ilson , Sunnie Kim , Florian Lordick , Manish A. Shah , Kohei Shitara , Ahsan Arozullah , Jung Wook Park , Jeffrey J. Raizer , Eric Van Cutsem , Rui-hua Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session: Esophageal and Gastric Cancer
Track
Esophageal and Gastric Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03505320
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr TPS260)
DOI
10.1200/JCO.2021.39.3_suppl.TPS260
Abstract #
TPS260
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
First Author: Manish A. Shah
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prevalence of claudin 18.2 (CLDN18.2) and the association of biomarkers with clinical activity in patients with gastric or gastroesophageal adenocarcinoma (G/GEJa) treated with zolbetuximab.
First Author: Diarmuid Martin Moran
Poster
2020 ASCO Virtual Scientific Program
Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2+/HER2–advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.
First Author: Manish A. Shah
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs